Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Scientific Reports|November 6, 2025
Mapping the phenomenology of intranasal 5-MeO-DMT in psychedelic-naïve healthy adultsAnna O Ermakova, Fiona Dunbar, Mathieu Seynaeve, et al.
Journal of Integrative Neuroscience|October 14, 2021
Perspectives on psychedelic treatment and research in eating disorders: a web-based questionnaire study of people with eating disordersFiona Harding, Mathieu Seynaeve, Johanna Keeler, et al.
BMJ Open|May 26, 2020
Clinical factors associated with progression to dementia in people with late-life depression: a cohort study of patients in secondary careGeorgia Peakman, Nishshanka Karunatilake, Mathieu Seynaeve, et al.
American Journal of Therapeutics|February 20, 2026
Psychedelic Therapy: A Primer for Primary Care Clinicians-5-Methoxy-N,N-DimethyltryptamineBurton J Tabaac, Kenneth Shinozuka, Anne Weisman, et al.
Journal of Psychopharmacology (Oxford, England)|February 27, 2026
A phase 2 uncontrolled, open-label study of intranasal BPL-003 (5-methoxy-<i>N,N</i>-dimethyltryptamine) in patients with treatment-resistant depressionClaire Roberts, Mathieu Seynaeve, Anna O Ermakova, et al.
The Journal of Neuropsychiatry and Clinical Neurosciences|May 17, 2022
Views on Using Psychoactive Substances to Self-Manage Functional Neurological Disorder: Online Patient Survey ResultsMatthew Butler, Mathieu Seynaeve, Abigail Bradley-Westguard, et al.
Therapeutic Advances in Psychopharmacology|May 22, 2020
Psychedelic treatment of functional neurological disorder: a systematic reviewMatthew Butler, Mathieu Seynaeve, Timothy R Nicholson, et al.
Journal of Psychopharmacology (Oxford, England)|April 15, 2024
Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-<i>N,N</i>-dimethyltryptamine benzoate) in healthy participantsJames Jonathan Rucker, Claire Roberts, Mathieu Seynaeve, et al.
Headache|September 20, 2024
Low-dose psilocybin in short-lasting unilateral neuralgiform headache attacks: results from an open-label phase Ib ascending dose studyJames Rucker, Matt Butler, Sadie Hambleton, et al.
Addiction (Abingdon, England)|December 10, 2025
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) for alcohol use disorder: An open-label, phase 2, proof-of-concept, clinical trialJohn Marsden, Michael Kelleher, Fiona Dunbar, et al.
Pageof 2